Characteristics of studies included in the meta-analysis
| Reference . | Year . | Country . | Center . | No. of participants . | Previous outcome . | Intervention/control . | Primary outcome . |
|---|---|---|---|---|---|---|---|
| 12 | 2012 | Multi-national | 139 | Prior early onset PE (n = 107) and/or SGA <10th percentile (n = 94) | Dalteparin 5000 IU + ASA vs ASA | PE prior to 34 wk GA | |
| 13 | 2012 | Italy | Multi-center | 135 | Prior PE (n = 52), prior loss >15 weeks (n = 49), prior SGA <10th percentile (n = 28), or prior abruption (n = 5) | Nadroparin 3800 IU vs no nadroparin | PE, loss >15 wk GA, SGA <10th percentile, and/or abruption |
| 9 | 2011 | France | Single center | 224 | Prior severe PE (n = 224) | Enoxaparin 4000 IU + ASA vs ASA | PE, SB, abruption, SGA <5th percentile |
| 11 | 2010 | France | Single center | 160 | Prior abruption (n = 160; 70 with PE) | Enoxaparin 4000 IU ± ASA vs ± ASA | PE, SB, abruption, SGA <5th percentile |
| 10 | 2009 | Canada | Multi-center | 116 | Prior early PE (n = 60) | Dalteparin 5000 IU ± ASA vs ± ASA | PE, SB, abruption, SGA <5th percentile |
| Prior abruption (n = 16) | |||||||
| Prior SGA <5th percentile (n = 21) | |||||||
| Loss >12 wk (n = 17) | |||||||
| 14 | 2005 | Italy | Single center | 80 | Prior PE with ACE DD (n = 80) | Dalteparin 5000 IU vs no dalteparin | PE, SGA <10th percentile |
| Reference . | Year . | Country . | Center . | No. of participants . | Previous outcome . | Intervention/control . | Primary outcome . |
|---|---|---|---|---|---|---|---|
| 12 | 2012 | Multi-national | 139 | Prior early onset PE (n = 107) and/or SGA <10th percentile (n = 94) | Dalteparin 5000 IU + ASA vs ASA | PE prior to 34 wk GA | |
| 13 | 2012 | Italy | Multi-center | 135 | Prior PE (n = 52), prior loss >15 weeks (n = 49), prior SGA <10th percentile (n = 28), or prior abruption (n = 5) | Nadroparin 3800 IU vs no nadroparin | PE, loss >15 wk GA, SGA <10th percentile, and/or abruption |
| 9 | 2011 | France | Single center | 224 | Prior severe PE (n = 224) | Enoxaparin 4000 IU + ASA vs ASA | PE, SB, abruption, SGA <5th percentile |
| 11 | 2010 | France | Single center | 160 | Prior abruption (n = 160; 70 with PE) | Enoxaparin 4000 IU ± ASA vs ± ASA | PE, SB, abruption, SGA <5th percentile |
| 10 | 2009 | Canada | Multi-center | 116 | Prior early PE (n = 60) | Dalteparin 5000 IU ± ASA vs ± ASA | PE, SB, abruption, SGA <5th percentile |
| Prior abruption (n = 16) | |||||||
| Prior SGA <5th percentile (n = 21) | |||||||
| Loss >12 wk (n = 17) | |||||||
| 14 | 2005 | Italy | Single center | 80 | Prior PE with ACE DD (n = 80) | Dalteparin 5000 IU vs no dalteparin | PE, SGA <10th percentile |
ACE DD, angiotensin converting enzyme deletion/deletion genotype; GA, gestational age; SB, stillbirth.